ITUS Corp. | Balance Sheet

Fiscal year is November-October. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
898.20
5,861.20
6,769.20
3,238.30
6,839.40
Total Accounts Receivable
175.00
400.00
-
-
-
Other Current Assets
160.60
60.60
126.50
162.10
174.60
Total Current Assets
1,233.80
6,321.80
6,895.70
3,400.40
7,013.90
Net Property, Plant & Equipment
8.40
11.90
43.50
156.60
52.70
Total Investments and Advances
4,197.30
-
-
-
-
Long-Term Note Receivable
5,000.00
-
-
-
-
Intangible Assets
-
2,721.70
2,396.40
2,071.10
1,745.80
Total Assets
10,439.50
9,055.40
9,335.60
5,628.10
8,812.40
Accounts Payable
527.20
540.20
374.70
373.20
480.30
Other Current Liabilities
2,684.30
1,269.30
219.10
95.50
409.20
Total Current Liabilities
3,211.50
1,809.50
593.80
468.80
889.50
Long-Term Debt
548.60
-
-
4,171.90
-
Other Liabilities
5,000.00
3,236.30
3,688.20
-
-
Total Liabilities
8,760.10
5,045.80
4,282.00
4,640.60
889.50
Common Equity (Total)
1,679.40
3,659.60
5,039.60
973.50
7,922.90
Total Shareholders' Equity
1,679.40
4,009.60
5,053.60
987.50
7,922.90
Total Equity
1,679.40
4,009.60
5,053.60
987.50
7,922.90
Liabilities & Shareholders' Equity
10,439.50
9,055.40
9,335.60
5,628.10
8,812.40
Preferred Stock (Carrying Value)
-
350.00
14.00
14.00
-

About ITUS

View Profile
Address
3150 Almaden Expressway
San Jose California 95118
United States
Employees -
Website http://www.ituscorp.com
Updated 09/14/2018
ITUS Corp. engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body's immunological response to the presence of a malignancy. The company was founded on November 5, 1982 and is headquartered San Jose, CA.